Shandong Weigao Group Medical Polymer Company (1066) H1 2024 earnings summary

Executive summary

• Revenue for 1H2024 was RMB6,635.7 million, down 3.8% year-over-year; net profit attributable to shareholders was RMB1,107.5 million, down 7.5% YoY but up 37.8% from 2H2023.

• Overseas revenue reached RMB1,720.1 million, up 6.7% YoY, now 25.9% of total revenue; export products grew over 20% YoY.

• R&D investment increased, with expenses at RMB301.6 million and R&D-to-sales ratio at 4.5%; 114 new product registrations and 64 patents obtained in 1H2024.

• Interim dividend proposed at RMB0.0919 per share, up from RMB0.0734 per share last year, subject to shareholder approval.

• Gross profit margin declined to 50.9% from 51.4% YoY due to price reductions from volume-driven procurements, partially offset by cost controls.

Financial highlights

• Gross profit was RMB3,376.4 million, down from RMB3,543.5 million YoY; adjusted revenue (excluding epidemic prevention) was RMB6.64 billion, down 2.2% YoY.

• Basic EPS was RMB0.25, diluted EPS RMB0.24, both lower than the prior year.

• Operating and free cash flow remained stable; net cash inflow from operating activities was RMB1,022.8 million; cash and bank balances at period end were RMB7,527.6 million.

• Gearing ratio stood at 17.9% as of 30 June 2024, slightly down from 18.6% at year-end 2023.

• Dividend payout ratio increased to 40% for 2023 and maintained for 1H2024, with interim dividend up 25% YoY.

Outlook and guidance

• Domestic medical institution activity normalized, boosting sales volume and market share of core products.

• Centralized procurement policies present short-term challenges but long-term opportunities; overseas business is expanding rapidly.

• Focus on platform-based, international, and digital strategies, with continued R&D and talent investment.

• Plans to expand direct marketing, strategic acquisitions, and product diversification, especially in high-tech and high-margin areas.

• Management emphasizes long-term value through product upgrades, cost control, and market expansion.